AlbertCLockhartMD

PubMed

• 8 citations
  T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.
  Manish A Shah, Takashi Kojima, Daniel Hochhauser, Peter Enzinger, Judith Raimbourg, Antoine Hollebecque, Florian Lordick, Sung-Bae Kim, Masahiro Tajika, Albert Craig L...> ;Future Oncology. 2022 Jul 19
• 2 citations
  An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic.
  James Kalmuk, Dan Rinder, Carl Heltzel, Albert Craig Lockhart> ;Expert Opinion on Drug Discovery. 2022 May 1
• 5 citations
  Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.
  Pei Jye Voon, Eric X Chen, Helen X Chen, Albert C Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N Vaishampayan, Vivek Subbiah, Albiruni R Razak, Daniel J Renouf, Sebast...> ;Journal of Experimental & Clinical Cancer Research. 2022 Feb 7
• 5 citations
  Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.
  Hiroyuki Arai, Andrew Elliott, Joshua Millstein, Joanne Xiu, Fang-Shu Ou, Federico Innocenti, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Natsuko Kawanishi...> ;Oncogene. 2021 Nov 2
• 4 citations
  Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
  Manik Amin, Feng Gao, Gretel Terrero, Joel Picus, Andrea Wang-Gillam, Rama Suresh, Cynthia Ma, Benjamin R. Tan, Maria Q. Baggstrom, Michael J. Naughton, Lauren Trull, ...> ;American Journal of Clinical Oncology. 2021 Sep 1
• 5 citations
  Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies.
  Kian-Huat Lim, Mateusz Opyrchal, Abhi Acharya, Nick Boice, Ningying Wu, Feng Gao, Jace Webster, Albert C. Lockhart, Saiama N. Waqar, Ramaswamy Govindan, Daniel Morgens...> ;European Journal of Cancer. 2021 Jul 10
• 16 citations
  Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.
  Jingyuan Wang, Joanne Xiu, Yasmine Baca, Francesca Battaglin, Hiroyuki Arai, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Joshua Millstein, Bodour Salhia, Richard M. Gol...> ;Oncogene. 2021 Jun 23
• Reply to M. Ratain
  Shing M. Lee, Nolan A. Wages, Karyn A. Goodman, A. Craig Lockhart> ;JCO Precision Oncology. 2021 Jun 4
• 14 citations
  Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
  Katrina S. Pedersen, Patrick M. Grierson, Joel Picus, A. Craig Lockhart, Bruce J. Roth, Jingxia Liu, Ashley Morton, Emily Chan, Jesse Huffman, Chris Liang, Andrea Wang...> ;Investigational New Drugs. 2021 Mar 18
• 7 citations
  A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
  Haeseong Park, Kerry J. Williams, Nikolaos A. Trikalinos, Sarah Larson, Benjamin R. Tan, Saiama N. Waqar, Rama Suresh, Daniel Morgensztern, Brian A. Van Tine, Ramaswam...> ;Cancer Chemotherapy and Pharmacology. 2021 Mar 1
• 8 citations
  Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.
  Shing M. Lee, Nolan A. Wages, Karyn A. Goodman, A. Craig Lockhart> ;JCO Precision Oncology. 2021 Feb 1
• 24 citations
  The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer.
  Hiroyuki Arai, Andrew Elliott, Joanne Xiu, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Joshua Millstein, Davendra Sohal, Richard M. ...> ;Clinical Cancer Research. 2021 Mar 25
• 1 citations
  A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinoma.
  Gregory Vlacich, Andrew Ballard, Shahed N. Badiyan, Matthew B. Spraker, Lauren E. Henke, Hyun Jik Kim, A. Craig Lockhart, Haeseong Park, Rama Suresh, Yi Huang, Cliff G...> ;Clinical and Translational Radiation Oncology. 2020 Nov 1
• 4 citations
  Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?
  Shayan Khalafi, Albert C. Lockhart, Alan S. Livingstone, Wael El-Rifai> ;Cancers. 2020 Oct 22
• 5 citations
  Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
  Chirag Patel, Sanjay Goel, Manish R. Patel, Lakshmi Rangachari, Jayson D. Wilbur, Yaping Shou, Karthik Venkatakrishnan, A. Craig Lockhart> ;Clinical Pharmacology in Drug Development. 2020 Oct 1
• 20 citations
  A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
  Colin D. Weekes, Albert C. Lockhart, Patricia LoRusso, Elaine Murray, Erica Park, Mike Tagen, Jatinder Singh, Indrani Sarkar, Lars Mueller, Hatem Dokainish, Geoffrey I...> ;The Oncologist. 2020 Oct 1
• 5 citations
  Role of Immunotherapy in Advanced Gastroesophageal Cancer
  Gretel Terrero, A. Craig Lockhart> ;Current Oncology Reports. 2020 Aug 17
• 116 citations
  Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
  Daniel V.T. Catenacci, Yoon-Koo Kang, Haeseong Park, Hope E. Uronis, Keun-Wook Lee, Matthew C.H. Ng, Peter C. Enzinger, Se Hoon Park, Philip J. Gold, Jill Lacy, Howard...> ;The Lancet. Oncology. 2020 Aug 1
• 10 citations
  FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial
  Haeseong Park, Ramon U. Jin, Andrea Wang-Gillam, Rama Suresh, Caron Rigden, Manik Amin, Benjamin R. Tan, Katrina S. Pedersen, Kian-Huat Lim, Nikolaos A. Trikalinos, Ab...> ;JAMA Oncology. 2020 Aug 1
• 27 citations
  The clonal evolution of metastatic colorectal cancer.
  Ha X. Dang, Bradley A. Krasnick, Brian S. White, Julie G. Grossman, Matthew S. Strand, Jin Zhang, Christopher R. Cabanski, Christopher A. Miller, Robert S. Fulton, S. ...> ;Science Advances. 2020 Jun 1
• 68 citations
  Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression
  Jessica Silva-Fisher, Ha X. Dang, Nicole M. White, Matthew S. Strand, Bradley A. Krasnick, Emily B. Rozycki, Gejae Jeffers, Julie G. Grossman, Maureen Highkin, Cynthia...> ;Nature Communications. 2020 May 1
• 41 citations
  First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low Dose Cyclophosphamide in Patients with Advanced Malignancies.
  Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Albert C. Lockhart, Kathleen N. Moore, Gerald Steven Falchook, Silvia C. Formenti, Aung Naing, Richard D. Carvajal, Le...> ;Clinical Cancer Research. 2020 Mar 1
• 76 citations
  Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
  Vivek Subbiah, Igor Puzanov, Jean-Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje, Juergen Wolf, José Baselga, Funda Meric-Bernstam, Jason Roszik, Eli L. Diamond, ...> ;Cancer Discovery. 2020 Feb 6
• 5 citations
  Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma.
  Patrick M. Grierson, Andrea S. Teague, Rama Suresh, Kian-Huat Lim, Manik Amin, Katrina S. Pedersen, Benjamin R. Tan, Jesse Huffman, Nick Boice, Lingling Du, Jingxia Li...> ;Journal of Gastrointestinal Oncology. 2020 Feb 1
• 4 citations
  A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
  Colin D. Weekes, A. Craig Lockhart, James J. Lee, Isrid Sturm, Adriaan Cleton, Funan Huang, Heinz-Josef Lenz> ;International Journal of Cancer. 2019 Nov 1
• Join now to see all